With manufacturers under increasing pressure to reduce costs, enhance compliance, and accelerate production timelines for high quality drugs, they are increasing their investments in innovative methods of solid dose manufacturing. While the pharmaceutical industry has been slow to adopt continuous manufacturing, it is gaining momentum with contract development and manufacturing organizations (CDMOs) such as Thermo Fisher Scientific, whose Greenville, North Carolina site is sunsetting traditional batch, solid dose production.
This eHandbook also reveals how Recipharm, another global CDMO, has invested in a full-range of development and production capabilities for oral solid dosage — from orphan drugs to blockbusters — to meet the industry’s growing demands.
Sponsored by: Adare Pharma Solutions